Theriva Biologics awarded €2.28M Spanish government funding for THERICEL cell platform

Theriva Biologics, Inc.

€1.33M unsecured loan lump sum in Q4 2024; interest 4.015%; repayable over 7 yrs after 3-yr grace.
€0.95M grant to Universitat Autònoma de Barcelona paid in annual installments over 3 years.
Funds to advance suspension cell platform for adenovirus/AAV therapies; scaling VCN-01 production.
Award validates proprietary A549 suspension cell platform for clinical manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.